Search
RESPOND Publications 2020

1 Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. Greenberg L, Ryom L, Wandeler G, Grabmeier-Pfistershammer K, Öllinger A, Neesgaard B, Stephan C, Calmy A, Rauch A, Castagna A, Spagnuolo V, Johnson M, Stingone C, Mussini C, De Wit S, Necsoi C, Campins AA, Pradier C, Stecher M, Wasmuth JC, Monforte AD, Law M, Puhr R, Chkhartishvilli N, Tsertsvadze T, Garges H, Thorpe D, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND Study Group.
J Acquir Immune Defic Syndr. 2020;83(3):240-250. Abstract

2 Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment. Mocroft, A, and RESPOND study group.
HIV Med. 2020. Abstract

3 How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium. B Neesgaard *, A Mocroft, L Greenberg, JF Larsen, G Wandeler, R Zangerle, H Günthard, C Smith, S De Wit, C Mussini, A Castagna, a D'Arminio Monforte, JJ Vehreschild, JC Wasmuth, C Pradier, N Chkhartishvili, F W.N.M. Wit, M Law, A Sönnerborg, A Bruguera, C Stephan, V Vannappagari, R Haubrich, O Kirk, D Podlekareva, J Kowalska, D Raben, J Rockstroh, L Peters, R Parades, K Grabmeier-Pfistershammer, A Scherrer, M Johnson, C Necsoi, V Borghi, C Muccini, T Tserstvadze, K Petoumenos, A Volny-Anne, J Lundgren, L Ryom, for the RESPOND study group
Microorganisms. 2020;8(8):E1164. Abstract


IN PRESS